Department of Medical Oncology, Hacettepe University Institute of Oncology, Sihhiye, Ankara 06100, Turkey.
Med Oncol. 2009 Dec;26(4):501-5. doi: 10.1007/s12032-008-9083-x. Epub 2009 Aug 18.
Hepatocellular carcinoma (HCC) is the most frequent malignant tumour of the liver. The risk of HCC in chronically hepatitis B virus (HBV) infected individuals is approximately 100-fold higher than in the uninfected population. Despite all therapeutic advances, the benefit of systemic chemotherapy in patients with HCC has limited. But, the phase III clinical trial conducted in patients with advanced HCC treated with sorafenib has showed significant improvements in both overall and progression-free survival Metastasis from liver to extrahepatic tissues is reported to be quite uncommon and has a poor prognosis. Here we present a case of HCC which metastasized to the vertebrae, lung and kidney in order of appearance and controlled with immunotherapy and antiviral therapy following resection.
肝细胞癌（HCC）是肝脏最常见的恶性肿瘤。慢性乙型肝炎病毒（HBV）感染者患 HCC 的风险比未感染者高约 100 倍。尽管有了所有的治疗进展，系统性化疗对 HCC 患者的益处仍然有限。但是，索拉非尼治疗晚期 HCC 的 III 期临床试验表明，总生存期和无进展生存期均有显著改善。肝外组织转移报道并不常见，且预后较差。这里我们报告了一个 HCC 病例，该病例按出现顺序转移到椎体、肺和肾脏，并在切除后通过免疫治疗和抗病毒治疗得到控制。
